233 related articles for article (PubMed ID: 10656425)
1. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
[TBL] [Abstract][Full Text] [Related]
3. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
[TBL] [Abstract][Full Text] [Related]
4. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
[TBL] [Abstract][Full Text] [Related]
7. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
9. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
[TBL] [Abstract][Full Text] [Related]
11. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Brewer GJ
Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
Hou G; Abrams GD; Dick R; Brewer GJ
Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
[TBL] [Abstract][Full Text] [Related]
13. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
[TBL] [Abstract][Full Text] [Related]
14. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Vine AK; Brewer GJ
Trans Am Ophthalmol Soc; 2002; 100():73-6; discussion 76-7. PubMed ID: 12545680
[TBL] [Abstract][Full Text] [Related]
15. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
17. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.
Medici V; Sturniolo GC
IDrugs; 2008 Aug; 11(8):592-606. PubMed ID: 18683094
[TBL] [Abstract][Full Text] [Related]
18. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
Brewer GJ
Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
[TBL] [Abstract][Full Text] [Related]
19. Anticopper efficacy of captopril and sodium dimercaptosulphonate in patients with Wilson's disease.
Wang XP; Yang RM; Ren MS; Sun BM
Funct Neurol; 2003; 18(3):149-53. PubMed ID: 14703896
[TBL] [Abstract][Full Text] [Related]
20. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
Brewer GJ
J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]